- Home
- DSP vs ELDN Comparison
DSP vs ELDN Comparison
Compare DSP & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ELDN
- Stock Information
- Founded
- DSP 1999
- ELDN 2004
- Country
- DSP United States
- ELDN United States
- Employees
- DSP N/A
- ELDN N/A
- Industry
- DSP EDP Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- ELDN Health Care
- Exchange
- DSP Nasdaq
- ELDN Nasdaq
- Market Cap
- DSP 220.3M
- ELDN 178.4M
- IPO Year
- DSP 2021
- ELDN N/A
- Fundamental
- Price
- DSP $14.60
- ELDN $3.62
- Analyst Decision
- DSP Strong Buy
- ELDN Strong Buy
- Analyst Count
- DSP 8
- ELDN 2
- Target Price
- DSP $21.75
- ELDN $12.50
- AVG Volume (30 Days)
- DSP 159.3K
- ELDN 890.7K
- Earning Date
- DSP 08-11-2025
- ELDN 08-18-2025
- Dividend Yield
- DSP N/A
- ELDN N/A
- EPS Growth
- DSP N/A
- ELDN N/A
- EPS
- DSP 0.13
- ELDN N/A
- Revenue
- DSP $306,484,000.00
- ELDN N/A
- Revenue This Year
- DSP $18.36
- ELDN N/A
- Revenue Next Year
- DSP $15.95
- ELDN N/A
- P/E Ratio
- DSP $112.61
- ELDN N/A
- Revenue Growth
- DSP 30.64
- ELDN N/A
- 52 Week Low
- DSP $8.70
- ELDN $2.38
- 52 Week High
- DSP $26.33
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- DSP 62.20
- ELDN 59.47
- Support Level
- DSP $13.32
- ELDN $3.63
- Resistance Level
- DSP $13.95
- ELDN $3.95
- Average True Range (ATR)
- DSP 0.50
- ELDN 0.24
- MACD
- DSP 0.11
- ELDN 0.01
- Stochastic Oscillator
- DSP 93.01
- ELDN 49.73
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.